Current status of antivascular therapy and targeted treatment in the clinic

Abstract

Antivascular and targeted therapy are now an integrated part of the treatment of myelogenous leukemias, GIST tumours, B-cell lymphomas and breast cancer. In various malignancies improved responses and prolongation of survival for several months is regularly reported. The progress in this field is relevant for hyperthermia. Heat has among other effects documented antivascular effects, and can be considered as one of the established methods in the field based on several randomised phase III studies. Hyperthermia should be considered for combination with other antiangiogenic agents.

Spin Trapping of Nitric Oxide by Hemoglobin and Ferrous Diethyldithiocarbamate in Model Tumors Differing in Vascularization

“…Vascularization and blood supply strongly influence tumor growth and invasiveness in vivo, and therefore determine the results of cancer treatment and prompt the important targets for anticancer therapy [38][39][40][41]. Particular types of tumors may differ significantly in their vascularization [42][43][44] and blood content, and this parameter must be taken into careful consideration when designing the appropriate treatment strategy.…”

Follow up your unexpected clinical observations!

“…However, frequently the clinical use of a drug or method is a two way process, with accumulation of new knowledge and facts at the bedside which has to be taken into account before the final progress can appear. Recently it has become clear that the term targeteted therapy sometimes may not be as targeted as initially expected, based on in vitro work or animal studies, as experience shows new side effects and complications due to a broader effect of the targeted therapy than initially thought of [1].…”